Overall, this shows that a novel class of PKC-θ inhibitor that specifically targets its nuclear import is required to target nPKC-θ activity and mesenchymal CTC and CSC phenotypes in aggressive, resistant metastatic diseases. Here, PRRT2 is linked to metastatic neoplasm.